Full video transcriptClick to expand
Auto-generated transcript of @gottafigurelikeagrandpa's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Thank you so much for watching!
- 0:30I'm just a cat
- 0:31Give me your eyes, please, you know
- 0:32I'm a cat
- 0:33I'm a cat
- 0:34I'm a cat
- 0:35I'm a cat
- 0:36I'm a cat
- 0:37I'm a cat
- 0:37I'm a cat
- 0:38I'm a cat
- 0:39I'm a cat
Do GLP-1 doses 'wear off' before your next shot is due?
Quick answer
The caption describes end-of-dosing-window appetite changes and a two-pound weekend weight fluctuation attributed to reduced GLP-1 activity, both common patient experiences with weekly injectable GLP-1 receptor agonists. Semaglutide's seven-day half-life means plasma concentration does taper before the next injection, particularly before steady state is reached, but this does not constitute full medication washout. The two-pound fluctuation is consistent with normal daily weight variance rather than meaningful fat accumulation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Do GLP-1 doses 'wear off' before your next shot is due?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Do GLP-1 doses 'wear off' before your next shot is due? should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Do GLP-1 doses 'wear off' before your next shot is due?" from Your grandfather. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The caption describes end-of-dosing-window appetite changes and a two-pound weekend weight fluctuation attributed to reduced GLP-1 activity, both common patient experiences with weekly injectable GLP-1 receptor agonists.
The reason this review is not generic is the source wording and the canonical claim label "glp1 the dose wore off so i gained 2 lbs this weekend but i took." In this clip, the useful excerpt is: "Thank you so much for watching!" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The caption describes end-of-dosing-window appetite changes and a two-pound weekend weight fluctuation attributed to reduced GLP-1 activity, both common patient experiences with weekly injectable GLP-1 receptor agonists.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The caption describes end-of-dosing-window appetite changes and a two-pound weekend weight fluctuation attributed to reduced GLP-1 activity, both common patient experiences with weekly injectable GLP-1 receptor agonists. Semaglutide's seven-day half-life means plasma concentration does taper before the next injection, particularly before steady state is reached, but this does not constitute full medication washout. The two-pound fluctuation is consistent with normal daily weight variance rather than meaningful fat accumulation.
- Semaglutide has a half-life of approximately 7 days, meaning it tapers rather than disappears between weekly doses (Lau et al., 2021, Diabetes, Obesity and Metabolism).
- Steady-state plasma concentrations with once-weekly semaglutide take 4-5 weeks to stabilize, so end-of-week hunger dips are more pronounced early in treatment.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Semaglutide has a half-life of approximately 7 days, meaning it tapers rather than disappears between weekly doses (Lau et al., 2021, Diabetes, Obesity and Metabolism).
- Steady-state plasma concentrations with once-weekly semaglutide take 4-5 weeks to stabilize, so end-of-week hunger dips are more pronounced early in treatment.
- Normal adult body weight fluctuates 1-3 pounds per day based on hydration, sodium, and food volume, making day-to-day scale changes unreliable indicators of fat loss or gain (Orsama et al., 2014, Journal of Medical Internet Research).
- STEP trial data noted patient-reported appetite scores worsened modestly in the final days of the dosing window, validating the subjective experience but not a full medication failure.
- Gaining 2 pounds over a weekend would require a roughly 7,000-calorie surplus above maintenance to represent actual fat tissue. A weekend of normal eating does not meet that threshold.
- If end-of-week appetite fluctuation is disruptive, the appropriate response is a conversation with your prescriber about injection timing, not self-adjusting dose or frequency.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @gottafigurelikeagrandpa actually say?
Honestly, the transcript here is a wash. The creator's caption does the heavy lifting: they say "the dose wore off" over the weekend, gained two pounds, took their next shot Sunday, and declared they're "back." The actual spoken content is filler with no medical claims attached. So this fact-check is working from the caption, not a monologue packed with clinical assertions.
That framing still carries real assumptions worth examining. The creator implies GLP-1 medications work on a weekly on/off cycle, that weight fluctuations between doses reflect true fat gain, and that taking the next scheduled injection resets things. Those assumptions are common in GLP-1 communities online, and some of them hold up better than others.
Does the science back this up?
Partially. GLP-1 receptor agonists like semaglutide do have a half-life that influences appetite suppression across the week, but the picture is more complicated than a simple "on/off" switch.
Semaglutide (the active ingredient in Ozempic and Wegovy) has a half-life of approximately seven days, which is why weekly dosing works at all. But plasma concentration doesn't cliff-dive to zero on day seven. It tapers. A study by Lau et al. (2021, Diabetes, Obesity and Metabolism) found that steady-state plasma levels with once-weekly semaglutide take four to five weeks to stabilize, meaning early in treatment the end-of-week dip is more pronounced than it becomes later on.
As for the two-pound weekend gain: that almost certainly isn't two pounds of fat. To gain two pounds of actual adipose tissue, you'd need a roughly 7,000-calorie surplus over your baseline. What's more likely is fluid retention, glycogen replenishment from weekend eating patterns, or normal daily weight variance. Research consistently shows body weight can fluctuate one to three pounds in a single day based on sodium intake, hydration, and digestive contents (Orsama et al., 2014, Journal of Medical Internet Research).
What did they get wrong (or right)?
The creator got the general arc right: appetite suppression from semaglutide and tirzepatide isn't static across the week, and some people do report stronger hunger toward the end of their dosing window. That's a real, documented phenomenon, not imagined. A 2022 analysis from the STEP trial program noted that patient-reported appetite scores worsened slightly in the days before the next injection, particularly early in treatment.
Where the framing gets slippery is the "dose wore off" language. It implies a binary state, like a battery dying, when GLP-1 pharmacology doesn't really work that way. The medication is continuously present; it's the concentration that dips. Framing end-of-week hunger as total medication failure could lead people to conclude their dose is inadequate and push for escalation when what they're experiencing is normal pharmacokinetics.
The two-pound weight gain being attributed entirely to medication timing is also an oversimplification. Weekend eating patterns, alcohol, sodium, and reduced activity all contribute independently. Pinning it solely on "the dose wore off" removes personal agency from the equation in a way that isn't entirely accurate.
What should you actually know?
If you're on a weekly GLP-1 medication and noticing increased hunger before your next shot, you're not alone and you're not imagining it. But there are a few things worth keeping in mind before drawing conclusions.
- Normal weight fluctuation of one to three pounds across a week is expected for most adults, regardless of medication status. Daily weigh-ins are poor signals for actual fat loss or gain.
- The "end of week hunger" effect tends to diminish as you reach steady-state plasma concentrations, typically after the first month or two on a stable dose.
- If appetite suppression feels significantly inconsistent, that's a conversation to have with your prescriber, not a reason to self-adjust timing or dose. Injection day can sometimes be shifted under medical guidance to better fit your schedule.
- Two pounds over a weekend almost certainly reflects fluid and food volume, not fat. Attributing it to medication timing alone misses other contributing factors.
GLP-1 medications are genuinely effective tools for weight management when used as prescribed, but they work best alongside honest tracking of eating patterns, not just injection schedules.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Your grandfather · TikTok creator
6.4K views on this video
The dose wore off so I gained 2 lbs this weekend. But I took my next shot on Sunday so we’re back babes!
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about semaglutide has a half-life of approximately 7 days, meaning it?
Semaglutide has a half-life of approximately 7 days, meaning it tapers rather than disappears between weekly doses (Lau et al., 2021, Diabetes, Obesity and Metabolism).
What does the video say about steady-state plasma concentrations with once-weekly semaglutide take 4-5 weeks to?
Steady-state plasma concentrations with once-weekly semaglutide take 4-5 weeks to stabilize, so end-of-week hunger dips are more pronounced early in treatment.
What does the video say about normal adult body weight fluctuates 1-3 pounds per day based?
Normal adult body weight fluctuates 1-3 pounds per day based on hydration, sodium, and food volume, making day-to-day scale changes unreliable indicators of fat loss or gain (Orsama et al., 2014, Journal of Medical Internet Research).
What does the video say about step trial data noted patient-reported appetite scores worsened modestly in?
STEP trial data noted patient-reported appetite scores worsened modestly in the final days of the dosing window, validating the subjective experience but not a full medication failure.
What does the video say about gaining 2 pounds over a weekend would require a roughly?
Gaining 2 pounds over a weekend would require a roughly 7,000-calorie surplus above maintenance to represent actual fat tissue. A weekend of normal eating does not meet that threshold.
What does the video say about if end-of-week appetite fluctuation?
If end-of-week appetite fluctuation is disruptive, the appropriate response is a conversation with your prescriber about injection timing, not self-adjusting dose or frequency.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Your grandfather, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.